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ABSTRACT
The American University in Cairo
Molecular Characterization of Extended-Spectrum-β-Lactamases (ESBL) Producing
Klebsiella pneumoniae and Escherichia coli among Hospitalized Patients in Oman
Lobna Mohamed Mourad
Advisers: Dr. Guillermo Pimentel and Dr. Rania Siam
Hospital-acquired infections due to ESBL-producing gram-negative rods are a
worldwide healthcare problem causing substantial patient morbidity and mortality. In the
Middle East, a significant increase in incidence and prevalence has been reported recently
due to the misuse of antibiotics and lack of coherent antimicrobial resistance (AR)
surveillance programs. The aim of the study was to determine the level of genotypic
diversity and mechanism of AR of E. coli and K. pneumoniae ESBL-producing isolates
from nosocomial infections among patients in Oman. 35 E. coli and 14 K. pneumoniae
isolates were used in the study. Antibiotic susceptibility testing (AST) and ESBL
screening was conducted via disk diffusion and E-test following CLSI (Clinical and
Laboratory Standards Institute) guidelines. ESBL producers were screened for blaCTX-M,
blaSHV, blaOXA, and blaTEM resistance markers via PCR. All PCR amplicons were
sequenced to determine their allelic variants. In order to demonstrate overall genotypic
diversity, Pulsed-Field Gel Electrophoresis (PFGE) analyses were done separately for all
E. coli and K. pneumoniae isolates. 40 (80%) isolates were determined to be ESBL
producing bacteria (27 E. coli and 13 K. pneumoniae). The highest level of AR (>70%)
was against tetracycline, ampicillin, nalidixic acid, cephalothin, and cefpodoxime. The
lowest level of AR was against chloramphenicol, amikacin and ticarcillin-clavulanic acid.
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Resistance against imipenem was not detected. Similarity of K. pneumoniae isolates
ranged from 61% to 100%. Three K. pneumoniae clusters (n= 7; 58%) had ≥ 80%
similarity suggesting high level of similarity. E. coli PFGE analyses showed an overall
similarity of 64% with 4 clusters (n= 14; 54%) showing 80% similarity. No correlation
was demonstrated between the AR pattern and genotypic similarity for either species.
Percentages of isolates with genetic markers for blaCTX-M, blaSHV, blaTEM, and blaOXA
were 73%, 24%, 68%, and 60% respectively. DNA sequencing analyses revealed that the
most common AR mechanism in these ESBL isolates is due to blaCTX-M-15 marker. In
addition, SHV-1, SHV-11, SHV-12, TEM-1, and OXA-1 contribute to the overall AR
mechanisms in nosocomial ESBL isolates from Oman. This is the first study
characterizing the AR mechanism of ESBL’s isolates from hospital-acquired infections in
Oman. The results showed that hospital-acquired E. coli isolates from Oman are more
diverse than K. pneumoniae. The blaCTX-M-15 is the most abundant mechanism conferring
ESBL phenotype on E. coli and K. pneumoniae, while the ESBL-SHV-type was the least
abundant.
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I.

LITERATURE REVIEW
In the early 1980s, third-generation cephalosporins were an important therapeutic tool

in treating severe bacterial infections due to β-lactamase-mediated resistance (Colodner,
2005; Perez et al., 2007). However, after the emergence of cephalosporin-resistant
(including ceftazidime) Escherichia coli and Klebsiella pneumoniae strains, the efficacy
of these antibiotics in saving lives was significantly compromised. According to Knothe
et al. (1983) there are three main characteristics that cause result in resistance to betalactam antibiotics: (1) production of beta-lactamases from chromosomal or plasmid
genes; (2) changes in the active site(s) resulting in the loss of the ability to bind with the
antibiotics; and (3) “Trapping” of the non-hydrolyzed antibiotics by highly induced
lactamases, which prevents drug transportation and uptake. The β-lactamase enzymes
were discovered in the early 1980s. These new beta-lactamase enzymes, called extendedspectrum-beta-lactamases (ESBLs), were found in common enteric bacilli and showed
distinct hydrolytic properties. The first ESBL enzymes discovered were shown to be
mainly derived from the original TEM and SHV β-lactamases as a result of point
mutations in the original enzymes resulting in the enzymes’ “extended spectrum” of
action (Falagas and Karageorgopoulos, 2009). For example, significant resistance was
characterized by single amino acid changes such as: Gly238Ser; Glu240Lys;
Arg164Ser; Arg164His; Asp179 Asn, and; Glu(Asp)104Lys (Perez et al.,
2007). Currently, the presence of these ESBLs is becoming a major health problem for
hospitalized patients, tertiary hospitals, facilities that offer long-term care, and even in the
community (Perez et al., 2007).
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Beta-lactamases are known to be one of the most heterogeneous groups of resistance
enzymes, with over 700 different beta-lactamases described. Although β-lactamases show
a great deal of amino acid variability, they are known to share a common overall
topology. The β-lactamases are globular proteins made up of alpha-helices and betapleated sheets (Perez et al., 2007). ESBLs are known to have the capability of
hydrolyzing several classes of antibiotics, such as penicillins, first-, second-, third-, and
fourth-generation cephalosporins and the monobactam antibiotic aztreonam (Perez et al.,
2007). However, ESBL derivatives from the TEM and SHV families are inhibited by βlactamase inhibitors that are available commercially, such as clavulanic acid, sulbactam,
or tazobactam. The inhibition of ESBLs by β-lactamase inhibitors is a crucial property
that it is used in the laboratory in the form of a phenotypic test that identifies whether a
certain bacterial isolate possesses an ESBL or not (Perez et al., 2007).
1. TEM β-lactamases:
The first TEM β-lactamase gene, designated ESBL gene as blaTEM-1, was discovered
in E. coli and Salmonella enterica serovar Paratyphi soon after the introduction of
ampicillin for clinical use in 1965 (Mroczkowska and Barlow, 2008). The TEM-1
enzyme itself was first isolated from a Greek patient named Temoniera, from a blood
culture of an E. coli isolate.
Since that time, the TEM-1 β-lactamase has been shown to occur world-wide and is
currently thought to be the most common resistance mechanism against β-lactam
antibiotics in Gram-negative bacilli (Sturenburg and Mack, 2003). During the 1970s,
blaTEM-1 became widespread among Enterobacteriaceae and by the early 1980s was
known to be the most prevalent resistance gene among clinical microbial populations.
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The TEM-1 β-lactamase is known to confer resistance primarily against penicillins,
including ampicillin (Mroczkowska and Barlow, 2008): up to 50-60% of plasmidmediated ampicillin resistance in E. coli is due to TEM-1 β-lactamase. TEM-1 is known
to be located on Tn3, a promiscuous transposon, in which it appears that several
rearrangement and transposition events resulted in the migration of the TEM-1 gene to
other bacterial strains, such as Haemophilus influenza and Neisseria gonorrhoeae
(Sturenburg and Mack, 2003).
TEM-1 as well as its biochemical twin, TEM-2, hydrolyze penicillins and firstgeneration cephalosporins; however, they cannot hydrolyze the oxyimino cephalosporins
(Sturenburg and Mack, 2003). In 1987, TEM-3 was the first TEM variant reported to
have an increased activity against the extended-spectrum cephalosporins. Since then the
number and variety of extended-spectrum TEM variants has increased rapidly. TEM is
one of the most commonly found ESBL enzyme types in E. coli and K. pneumoniae, in
which over 160 different variants are found in this family (Colodner, 2005; Mroczkowska
and Barlow, 2008).
The point mutations that are clustered in particular areas of the enzyme are what
determine the broader spectrum of resistance. As described by Joris et al. (1991) these
point mutation sites are adjacent to four evolutionarily conserved structural regions that
form the active site of the enzyme (Sturenburg and Mack, 2003). It has been shown that
in the progenitor enzyme all these elements are very close to the active site, in which it is
thought that the amino acid substitutions result in the enlargement of the active site
resulting in novel enzyme-substrate interactions that take place between the large
oxyimino substituents of the extended-spectrum cephalosporins (Sturenburg and Mack,

5

2003). In fact, the accelerated evolution of the blaTEM sequence and phenotypic diversity
presents it as a good model for studying the principles of evolutionary biology with
clinical applications (Mroczkowska and Barlow, 2008).
Genetic recombination as well as protein engineering have demonstrated novel βlactamases phenotypes. For example, ceftazidime resistant mutants can be generated
using a wide variety of techniques such as insertional mutagenesis, site-directed and sitesaturation mutagenesis, random replacement mutagenesis, DNA shuffling, and random
insertional deletional strand exchange mutagenesis (Babic et al., 2006). These
experiments are mainly used in order to show how many substitutions can be generated to
alter the TEM-1 phenotype. In some cases these experiments predicted the emergence of
novel phenotypes before they appeared clinically (Babic et al., 2006).
The fact that some blaTEM alleles confer resistance against cephalosporins and
penicillins might indicate the possible increased prevalence of these alleles due to their
advantageous phenotypes. Therefore, it is predicted that ESBL blaTEM alleles would
either co-exist with blaTEM-1 or replace it as it is the most frequently found allele in
clinical settings where cephalosporins are mainly used (Babic et al., 2006). However,
neither of these predictions has yet proven to be true among clinical bacterial isolates,
and blaTEM-1 is still the most common allele conferring resistance to first-line
cephalosporins (Mroczkowska and Barlow, 2008).
2. SHV β-lactamases:

The SHV-type ESBL is known to be one of the most common ESBL types in clinical
isolates compared to other ESBL types. The designation SHV refers to the sulfhydryl
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variable, inhibition of the SHV activity by p-chloromercuribenzoate is substrate-related;
and varies depending on the substrate used for the assay; however, studies never
confirmed the validity of this hypothesis (Paterson and Bonomo, 2005).
The SHV β-lactamase family originally was found in Klebsiella spp.. The progenitor
of the SHV family, SHV-1, is universally present in K. pneumoniae. It has been shown
that in most K. pneumoniae strains, the SHV-1 gene can be found on the bacterial
chromosome, which may suggest that this gene may have evolved in Klebsiella and was
subsequently incorporated into a plasmid that resulted in its spread to other
enterobacterial species (Sturenburg and Mack, 2003). SHV-1 confers resistance to
ampicillin, piperacillin, and ticarcillin, which are broad-spectrum penicillins; however,
they do not confer resistance to the oxyimino substituted cephalosporins.
In 1983, three K. pneumoniae and one Serratia marcescens strains from patients in
West Germany showed transferable resistance to cefotaxime and other new
cephalosporins. Later it was shown that mutations in SHV-1 resulted in the emergence of
the new plasmid-encoded β-lactamase, SHV-2, in which the amino acid at position 238
was changed from glycine to serine resulting in enhancement of the affinity of the SHV-1
β-lactamase to the oxyimino cephalosporins. In addition, this mutation led to a noticeable
rise in the MIC to cefotaxime as well as slight rise in the MIC to ceftazidime (Sturenburg
and Mack, 2003). Since that time, additional SHV ESBL variants have been reported
containing various amino acid alterations, such as those in positions 179, 205, and 240,
that contribute to an increased ESBL phenotype. Currently, there are over 40-SHV ESBL
enzymes where changes in amino acid sequences have conferred the ability to hydrolyze
the new cephalosporins (Sturenburg and Mack, 2003).
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SHV ESBL-producing bacteria have been detected in various members of the
Enterobacteriaceae. In addition, Pseudomonas aeruginosa and Acinetobacter spp. isolates
have caused significant nosocomial outbreaks due to the production of ESBL by SHV
enzymes (Paterson and Bonomo, 2005). Unlike TEM, only SHV-10 was reported as an
SHV variant with an inhibitor resistant phenotype, where in position 130 the amino acid
serine is replaced by glycine (Sturenburg and Mack, 2003). It was shown that SHV-2 and
SHV-5 have the ability to hydrolyze cefepime where patients engaged in a retrospective
study and infected with ESBL-producing bacteria with susceptibility to cefepime
(Sturenburg and Mack, 2003).
3. CTX-M β-lactamases:

The CTX-M-type ESBLs now exceed over 40 different types, in which they are
divided into five different clusters based on amino acid identities: group CTX-M-1
includes CTX-M-1, -3, -10, -12, -15, -28, -30 and FEC-1; group CTX-M-2 includes
CTX-M-2, -4, -5, -6, -7, -20, and Toho-1; group CTX-M-8 includes only CTX-M-8;
group CTX-M-9 includes CTX-M-9, -13, -14, -16, -17, -19, -21, -24, -27, and Toho-2,
and finally; group CTX-M-25 includes CTX-M-25 and CTX-M-26 (Pitout et al., 2005).
CTX-M (cefotaxime) β-lactamases possess strong hydrolytic activity against cefotaxime.
Bacterial isolates that possess CTX-M enzymes usually show MIC (minimum inhibitory
concentration) levels against cefotaxime in the resistant range (>64 µg/ml), but MIC
levels against ceftazidime in the susceptible range (2 to 8 µg/ml). However, it has been
reported that some CTX-M positive isolates have the ability to hydrolyze ceftazidime,
conferring resistance against this particular cephalosporin (Paterson and Bonomo, 2005).
It has also been shown that cefepime is efficiently hydrolyzed by the CTX-M enzymes,
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for which MIC levels against cefepime are higher than for other ESBL-producing
bacteria.
Unlike clavulanic acid, tazobactam shows a 10-fold inhibitory effect against CTX-M
β-lactamases. It has been observed in several species that they harbor either both CTX-M
and SHV ESBLs or CTX-M and AmpC β-lactamases. Toho-1 and Toho-2 β-lactamases
are structurally related to the CTX-M β-lactamases. Similar to CTX-M β-lactamases,
Toho-1 and Toho-2 hydrolytic activity is stronger against cefotaxime than ceftazidime
(Paterson and Bonomo, 2005).
There has been a rapid spread of the CTX-M β-lactamases, and they have now been
detected on every continent. Previously, CTX-M β-lactamases were mainly found in
three different geographical regions: South America, Eastern Europe, and, the Far East
(Paterson and Bonomo, 2005). Although it was observed in the past that CTX-M βlactamases were infrequently detected in Western Europe and North America, the
presence of CTX-M has been reported in recent years in these regions. Subsequently, the
CTX-M β-lactamases have become widespread in India and China, and it is speculated by
some that the CTX-M type of β-lactamases is the most frequent ESBL type. Several
studies have shown the presence of identical CTX-M β-lactamases in different
geographic areas, such as CTX-M-3 that was discovered in Poland and Taiwan (Paterson
and Bonomo, 2005).
4. OXA β-lactamases:
OXA β-lactamases are named after their ability to hydrolyze oxacillin. They are
predominantly found in P. aeruginosa but have been reported in several Gram-negative
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species (Paterson and Bonomo, 2005). The hydrolysis rate of OXA β-lactamases for
cloxacillin and oxacillin is known to be more than 50% compared to that of
benzylpenicillin.
The OXA ESBLs were discovered originally in P. aeruginosa samples from a
hospital in Ankara, Turkey (Paterson and Bonomo, 2005). Novel derivatives of OXA-10,
OXA013 and OXA-18 were discovered in France in P. aeruginosa isolates from hospitalacquired infections. It has been shown that the ESBL OXA-type β-lactamases evolution
from the parent enzymes with narrower spectra resembles the evolution of the TEM- and
SHV-type ESBLs (Paterson and Bonomo, 2005).
OXA-1 is the most common OXA β-lactamase with a prevalence rate of 1 to 10% in
isolates of E. coli that possess an OXA β-lactamase (Paterson and Bonomo, 2005). Most
of the OXA β-lactamases do not significantly hydrolyze the extended-spectrum
cephalosporins and hence they are not considered to be ESBLs. However, OXA-10 is
known to weakly hydrolyze cefotaxime, aztreonam, and ceftriaxone, resulting in most
organisms having a reduced susceptibility to these antibiotics. OXA-11, -14, -15, -16, 17, -18, -19, -28, -31, -32, -35, and -45, are all OXA ESBLs that confer resistance to
cefotaxime, and in some cases ceftazidime and aztreonam (Paterson and Bonomo, 2005).
5. Overview of ESBL Producing Bacteria in the Middle East:
Since the 1980s, ESBL-producing bacteria have rapidly spread across many different
geographical regions. This spread may be a result of the transmission of plasmids among
unrelated Enterobacteriaceae, a phenomenon observed in French hospitals (Moubareck et
al., 2005), or by the clonal dissemination of the enzyme-producing microorganisms. In
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several cases, transfer of ESBL-producing bacteria between hospitals followed by their
clonal expansion and/or horizontal transfer of plasmids with ESBL genes may take place.
Although ESBL-producing bacteria have been reported in many countries, few studies
providing antibiotic resistance (AR) data in the Middle East have been published. The
majority of the studies performed to date represent only hospitalized patients where the
transfer rate of ESBL from patient fecal flora to community subjects is still unknown
(Moubareck et al., 2005). For example, a 5-year study in Lebanon (1997 - 2001), at Saint
George Hospital, showed that among 4,299 E. coli and 1,248 K. pneumoniae isolates, 2%
and 20%, respectively, were ESBL positive (Moubareck et al., 2005). However, no
epidemiological studies on ESBL–producing bacteria have been conducted recently in
Lebanon. Another study done by Moubareck et al. (2005) revealed that out of 118
isolates, 72 (61%) were shown to be ESBL positive with E. coli being the most abundant
ESBL carrier. Molecular data showed that CTX-M-15 was the most prevalent ESBL
produced, while SHV-5a was detected in the remaining isolates (Moubareck et al., 2005).
In Egypt, recent studies on Enterobacteriaceae revealed 70% AR rates to thirdgeneration cephalosporins (Khalaf et al., 2009). A survey from 2001 to 2002 covering
medical centers in Northern and Southern European countries, Saudi Arabia, Lebanon,
Egypt, and South Africa showed that the highest incidence of ESBL-producing bacteria
was in Egypt. Recently, CTX-M-type ESBLs have been reported in Egypt, with CTX-M15 being the most prevalent ESBL reported in the Middle East and North Africa (Khalaf
et al., 2009). Also, CTX-M-14 has been detected in Egypt and Tunisia. A study by
Khalaf et al. (2009) showed that all 5 clinical isolates tested were ESBL positive and
resistant to cefotaxime (CTX). Molecular analyses identified blaCTX-M-14 in K.
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pneumoniae and Enterobacter cloacae and blaCTX-M-15 in E. coli. This study is considered
to be the first report of CTX-M-14 in Egypt, North Africa, or the Middle East for K.
pneumoniae and E. coli (Khalaf et al., 2009).
In Saudi Arabia, a study by Al-Agamy et al. (2009) revealed that out of a total of 400
K. pneumoniae isolates collected from two hospitals in Riyadh, 55% were ESBL positive.
PCR analyses showed that 97.3%, 84.1%, and 34.1% of ESBL isolates were positive for
SHV, TEM, and CTX-M β-lactamase genes, respectively. Also CTX-M-1 and CTX-M-9
were identified with a prevalence of 60% and 40%, respectively (Al-Agamy et al., 2009).
In Kuwait, a study by Ensor et al. (2008) showed that CTX-M-15 is the predominant
ESBL gene among K. pneumoniae and E. coli isolates from both hospital and community
patients. Another study in Oman by Al-Lawati et al. (2000) showed that 2 out of 13 E.
coli isolates and 3 out of 20 Klebsiella spp. isolates were ESBL positive, in which they
were resistant to aztreonam and ceftazidime, but sensitive to ceftazclav.
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II.

PROJECT OBJECTIVES
Very minimal ESBL surveillance and molecular characterization studies has been
carried out in the Middle East, which is a serious threat to the public health because
of the increasing incidence of ESBL infections in the region. This study from Oman
can be the start of a more thorough surveillance system throughout the Middle East.
Isolates for this study were extracted from hospitalized patients with nosocomial
infections in 2006. The objectives of the study are the following:


To determine the percentage of E. coli and K. pneumoniae isolates that produce
ESBL enzymes.



To determine the AR mechanism of ESBL isolates by sequencing four resistant
markers (blaCTX-M, blaSHV, blaTEM, and blaOXA) responsible for this phenotype.



To compare DNA and amino acid sequence of ESBL producing isolates from
hospital-acquired infections in Oman to isolates from other geographical regions.



To determine the amount of genetic variability present in E. coli and K.
pneumoniae isolates by molecular fingerprinting using Pulsed Field Gel
Electrophoresis (PFGE).
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III.

MATERIALS AND METHODS

1. Specimen Collection, Identification and Archiving:

Bacterial isolates were donated for this study by Dr. Suleiman Busaidy, Director
of the Central Public Health Laboratory (CPHL) in Oman. Isolates were taken from
patient blood cultures at Public Health Hospitals as part of routine care for suspected
nosocomial infections (sepsis). Highly-resistant Gram-negative rods identified by clinical
laboratories were transferred to Dr. Busaidy’s lab for further confirmation. Isolates were
shipped to NAMRU-3 in chocolate agar slants at room temperature for advanced
molecular characterization.
At NAMRU-3 samples were processed for ESBL identification and long-term
archiving. All isolates were cultured on MacConkey agar (Becton Dickinson, USA) in a
non-CO2 incubator at 37°C for 24 hours. Phenotypic identification was carried out using
the 5-biochemical differential tubes test (Kligler's Iron Agar, Motility Indole Ornithine
Medium, Lysine Iron Agar, Simmons Citrate Agar and Urea Broth) (Becton Dickinson,
USA), as per NAMRU-3 standard operating procedures (Manual of Clinical
Microbiology, ASM, 2009). Confirmation of K. pneumoniae identity was carried out
using the Analytical Profile Index for Enterobacteriaceae (API-20E) (BioMerieux,
France). Following confirmation, isolates were inoculated aseptically using sterile cotton
swabs (Becton Dickinson, USA) into 1.8 mL tubes and preserved in BrainHeart Infusion
broth with 15% glycerol and stored at -70°C.
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2. Antibiotic Susceptibility Testing (AST):

AST was conducted and interpreted following CLSI (Clinical and Laboratory
Standards Institute) guidelines and/or manufacturer’s instructions (CLSI, Wayne, PA
USA). Tables 1 and 2 show the antibiotics tested using Kirby-Bauer and/or E-test (AB
Biodisk, Solna, Sweden) methods, respectively, to determine the AR profile of each
isolate.
Briefly, a bacterial suspension was prepared using 0.85% saline solution and
turbidity adjusted to the equivalent of a 0.5 McFarland Standard. A sterile cotton swab
was dipped into the bacterial suspension and used to inoculate Mueller-Hinton agar plates
in three directions to ensure uniform growth of bacteria. Inoculated plates were left for 15
minutes to dry, antibiotic discs or E-test strips were placed on the agar surface using an
automatic dispenser, and the plate incubated in a non-CO2 incubator at 37°C for 18-20
hours. ESBL production was detected using the double-disk approximation method
described by Jarlier et al. (1988). Utilizing CAZ or CTX in combination with clavulanic
acid, the zone of inhibition was measured. A zone of inhibition ≥ 5 mm, when compared
to CAZ or CTX without clavulanic acid, indicates an ESBL positive isolate (CLSI,
Wayne, PA USA).
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3. Pulsed-Field Gel Electrophoresis (PFGE):

Methods to prepare bacterial plugs and DNA restriction digestion for ESBLproducing E. coli and K. pneumoniae isolates were similar. Colonies were scraped from a
MacConkey agar plate using a sterile cotton applicator and diluted in a cell suspension
buffer (CSB) (1 M Tris, pH8.0, 0.5 M EDTA, pH 8.0) until an optical density of 0.5-0.55
was achieved using a turbidity meter (Dade Behring, CA, USA). An aliquot of bacterial
suspension was gently mixed with an equal volume of melted agarose (pulsed field
grade), and dispensed into pre-formed plug molds. PFGE plugs were made by
transferring 400 µl of bacterial suspension into 1.5 ml reaction tubes that were mixed
with 20 µl of proteinase K and 400 µl of the melted 1% SeaKem Gold Agarose(SKG):
1% sodium dodecyl sulfate (SDS) (47.5 ml of TE buffer, 2.5 ml 20% SDS and 0.5 g
SKG). Immediately, the mixture was dispensed into the wells of the plug molds and left
to solidify for 20 minutes. After the plugs solidified, they were transferred into 50 ml
falcon tubes containing 5 ml cell lysis buffer (CLB) (1 M Tris, pH8.0, 0.5 M EDTA, pH
8.0, 5 g Sarcosyl) and 25 µl proteinase K. The BD Falcon 50-ml conical tubes were
incubated at 54°C in a shaker for 2 hours with vigorous shaking. After incubation, the
lysis buffer was discarded and plugs were washed twice with 10-ml sterile water and four
times with 10-ml TE buffer. Each wash was for 20 minutes and after the final wash the
plugs were stored in TE buffer at 4°C until digestion.
Bacterial DNA was digested using the XbaI enzyme (New England BioLabs,
Ipswich, MA, USA). Salmonella enterica ser. Braenderup (Tenover et al., 1995) was
used as control and ladder to determine DNA fragment sizes and genetic relationships
among isolates based on PFGE patterns. Briefly, each plug was cut with a razor blade
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into a 2-mm slice and placed into a 1.5-ml tube with 200 µl of incubation buffer (180 µl
sterile water and 20 µl 10X NE buffer (New England BioLabs, Ipswich, MA, USA)).
Tubes were incubated at 37°C in a water bath for 15 minutes. The restriction solution was
prepared by mixing 1755 µl of distilled-sterile water, 200 µl 10X NE buffer (New
England BioLabs, Ipswich, MA, USA), 20 µl 100X BSA (New England BioLabs,
Ipswich, MA, USA), and 25 µl 20,000 U/ml XbaI (New England BioLabs, Ipswich, MA,
USA). After incubation, the 200-μl incubation buffer was discarded and 200 µl of
restriction solution was added to the plugs. Tubes were incubated in a water bath at 37°C
for 4 hours. Later, the restriction solution was discarded and 200 µl of 0.5 X TBE were
added to the tubes. After restriction, the plugs were loaded into a 1% SKG agarose gel
(0.5 X TBE). Plugs were placed at the bottom of a 10-well comb with control plugs at
both ends. The plugs were dried using tissue paper to ensure no excess buffer remained in
the plugs. Agarose gel was poured into the casting gel tray, left to solidify for 30 minutes
and loaded into the buffer chamber of a CHEF DRII or DRIII pulsed field apparatus
(Bio-Rad, Hercules, CA, USA) containing 0.5X TBE at 14°C. PFGE running conditions
were as following: 6.0 V/cm for 19 hours for K. pneumoniae and 20 hours for E. coli at
switch times from 2.2-54.2 seconds. PFGE patterns were observed by staining the gel
with ethidium bromide for 20 minutes and de-staining three times with distilled water for
20 minutes each. Photos were taken with the Gel Doc XR System (Bio-Rad, Hercules,
CA, USA). The banding pattern of the gels was then analyzed and dendograms were
generated using the BioNumerics software.
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4. Detection of Antimicrobial Resistance Alleles via PCR and Sequencing:

DNA extraction was carried out using the SV Minipreps Promega DNA
Purification System (Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Amplification of the blaTEM, blaSHV, blaCTX-M, and blaOXA genetic markers
was carried out in a final volume of 25 µl using the following reaction: 10X buffer
(Promega, Madison, WI, USA ), 10 µM dNTP mix (Promega), 30µM PCR-specific
forward primer, 30µM PCR-specific reverse primer, 5U/µl Taq polymerase (Promega,
Madison, WI, USA), 25 µM MgCl2 (Promega, Madison, WI, USA), 2 μl DNA and
Molecular Biology Grade water. The PCR reactions were conducted in a GeneAmp PCR
System 9700 (Applied Biosystems, Carlsbad, CA, USA). The amplicon-specific primers
are shown in Table 3 (Chen et al., 2004).
PCR Cycling Conditions
Genes

Initial denaturation

Amplification cycles (30 times)

(1 cycle)
blaTEM

94°C 5 min

blaSHV

95°C 10 min

blaCTX-M

94°C 5 min

blaOXA

94°C 5 min

Final extension
(1 cycle)

94°C 30 sec, 52°C 45 sec and 72°C
45 sec
95°C 30 sec, 55°C 1 min and 72°C 1
min
94°C 30 sec, 57°C 45 sec and 72°C
45 sec
94°C 30 sec, 52°C 45 sec and 72°C
45 sec

72°C 7 min
72°C 7 min
72°C 7 min
72°C 7 min

PCR amplicons were analyzed by gel electrophoresis on 1.5% agarose gel (BioRad, Hercules, CA, USA) using 1X TBE (Promega, Madison, WI, USA ) as running
buffer. The gels were run at 100V for 40 minutes followed by staining for 20 minutes on
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ethidium bromide and destaining for 30 minutes with distilled water. Gels were
visualized and photographed under UV light.
5. Sequencing Reactions:

Only isolates that showed a single PCR amplicon were selected for sequencing
analyses. Forward and reverse sequencing was carried out for all amplified targets. After
amplification, the PCR amplicons were purified and sequenced. In the purification step,
10 µl of the PCR product was added to 5 µl of ExoSAP-IT reagent (USB, Cleveland,
Ohio) and the mixture was incubated in a thermocycler for 15 minutes at 37°C followed
by 15 minutes at 80°C. The purified PCR product was then subjected to cycle sequencing
using the Big Dye Fluorescent System (Applied Biosystems, Carlsbad, CA, USA). The
reaction was carried out in a total volume of 20 μl with the following reagents: 2 µl of the
purified PCR product, 5X sequencing buffer (Applied Biosystems, Carlsbad, CA, USA),
Big Dye Terminator V3.15X (Applied Biosystems, Carlsbad, CA, USA), molecular
biology grade water, and either 3 µM forward primer or 3µM reverse primer. The
sequencing reaction was performed under the following conditions: initial denaturation at
96°C for 10 sec, followed by 25 cycles of 96°C for 10 sec, 50°C for 5 sec and 60°C for 4
min. Reactions were kept at 4°C or stored at -20°C until purification of the sequenced
products using the Performa Gel Filtration Cartridge (Edge Biosystems, Gaithersburg,
Maryland, USA) according to manufacturer’s instructions. 10 µl of sequenced products
were loaded into the ABI 3100 (Applied Biosystems, Carlsbad, California, USA)
automated sequencer plate.
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6. Sequence Data Analyses:

The nucleotide sequences were compared using BLAST and analyzed using the
BioEdit Clustal W program (Hall TA., 1999) as well as the BioNumerics software
(Applied Maths, Inc. Austin, TX). Sequences were first assembled, aligned, and edited
using the BioNumerics software. After that, sequences were imported to BioEdit where
they were aligned with a known sequence and edited further. The nucleotide sequence
was then converted to the amino acid sequence. The amino acid sequences were analyzed
using the website http://www.lahey.org/studies/, which is maintained by the Lahey
Clinic, in order to assign a specific TEM, SHV, CTX-M, or OXA allele to each isolate.
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IV.

RESULTS

1. Antimicrobial Susceptibility and ESBL Screening
50 Gram negative isolates were collected in 2006 from blood cultures of patients
with suspected nosocomial infections at Public Health Hospitals in Oman. Out of 50
isolates (36 E. coli and 14 K. pneumoniae) tested, 40 (80%) were confirmed as ESBLproducing. Out of the 40 isolates, 27 (75%) E. coli and 13 (92.8%) K. pneumoniae, are
ESBL producing species, which was determined using the double-disk approximation
method as described in the materials and methods section. Antibiotic susceptibility
testing showed that the highest level of AR (>70%) was against five different antibiotics,
AM, CF, CPD, NA, and TE (Figure 3), in which the results were interpreted according to
the measurement of the zone of inhibition using the CLSI standard guidelines. 47 (94%)
isolates showed resistance against ampicillin (AM), which implies that it should not be
used in treating nosocomial infections caused by ESBL-producing bacteria. Also 46
(92%) of the isolates were resistant to cephalothin (CF) also suggesting the poor
antimicrobial activity of this particular agent against ESBL bacteria. Cefpodoxime
(CPD), nalidixic acid (NA), and tetracycline (TE) all demonstrated high resistance
ranging from 82% to 74%. On the other hand, the lowest level of AR (≤16%) was shown
against chloramphenicol (C), amikacin (AN) and ticarcillin-clavulanic acid (TIM) where
16% to 6% of the isolates were resistant to these three antimicrobial agents, suggesting
the effectiveness of these antibiotics against ESBL-producing bacteria (Figure 3). The
decreased percentage of resistance against ticarcillin-clavulanic acid (TIM) can highly be
due to the fact that ticarcillin is combined with clavulanic acid, which is a β-lactamase
inhibitor, and hence less number of bacteria species survived. This is also the case with
ampicillin/sulbactam (SAM); however, the a higher percentage of resistance was

21

observed for this compound and this can be due to either the strength of ampicillin as an
antimicrobial agent or decreased effectiveness of sulbactam as a β-lactamase inhibitor
compared to that of clavulanic acid.
No resistance was detected against imipenem (IPM), in which none of the isolates
was resistant to IPM suggesting the effectiveness of this antimicrobial agent against
ESBL bacteria (Figure 3). Therefore, in terms of susceptibility, 100% of all the isolates
were susceptible to IPM (Figure 1). In terms of intermediate resistance, Ticarcillinclavulanic acid (TIM) was shown to have the highest number of intermediate isolates (n=
22), which also suggests the poor antimicrobial activity of this agent against ESBL
bacteria (Figure 2). Based on E-test, 76% of the isolates conferred resistance to
ceftriaxone (TX), while 50% of the isolates were susceptible to cefepime (PM) (Table 4).
The E-test results indicate that less resistance has been observed against fourth generation
cephalosporins (PM) compared to the antimicrobial agent that belongs to the third
generation cephalosporins (TX).
2. Characterization of ESBL Genes
The forty isolates that tested positive for ESBL production were then analyzed to
identify the type of ESBL present. Plasmid DNA was extracted and PCR utilized for the
four major type markers. The percentages of isolates carrying the plasmid-encoded
genetic markers, blaCTX-M, blaSHV, blaTEM, and blaOXA were 73%, 24%, 68%, and 60%
respectively. The band sizes for blaCTX-M, blaSHV, blaTEM, and blaOXA were 766 bp, 720
bp, 650 bp, and 600 bp respectively (Figures 4, 5, 6, & 7).
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Twenty-one E. coli and 8 K. pneumoniae isolates were positive for blaCTX-M
(Figure 4). These CTX-M type ESBL genes were then sequenced using the Big Dye
protocol to identify the subtypes present. DNA sequencing analyses using the BioEdit
and BioNumerics software packages, revealed that all blaCTX-M positive isolates carried
the CTX-M-15 allele (Figures 8 a & b). Isolate 06-012018 initially tested negative for
any ESBL phenotype (i.e. no resistance to 3rd or 4th-generation cephalosporins).
However, PCR and sequencing analyses subsequently demonstrated that it was positive
for only CTX-M-15, which implies that the isolate did not possess the ESBL phenotype
due to the ESBL gene not being expressed (Table 5).
Isolates of K. pneumoniae (n=10) were the only ones with blaSHV markers (i.e. no
E. coli isolates possessed the SHV type of ESBL), which is usually the case presented by
the Klebsiella spp. (Figure 5). Subsequent sequencing analyses using the Lahey Clinic
webpage, amino acid sequences revealed that 4 isolates possessed the SHV-11 subtype, 4
isolates the SHV-12 subtype, and the SHV-1 subtype was detected in 2 isolates (Figures
11 a & b). This indicates that sequencing analyses showed that only 8 isolates possessed
the ESBL SHV-type, since SHV-1 is not categorized as an ESBL.
According to the PCR amplification, thirty-two isolates were positive for blaTEM
allele (Figure 6). All of these isolates (16 E. coli and 6 K. pneumoniae) carried the
blaTEM-1 subtype showing that no ESBL TEM-type isolates have identified, since the
TEM-1 is the parent enzyme from which ESBL TEM-types later originated (Figures 9 a
& b). In addition, sequencing analyses revealed that all OXA-positive isolates (18 E. coli
and 4 K. pneumoniae) were shown to possess the most common OXA allele, OXA-1
allele (Figure 7, 10 a & b).
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3. Genotypic Analyses
PFGE was carried out in order to establish the genotypic fingerprint of the E. coli
and K. pneumoniae isolates separately. As shown in the materials and methods section,
the protocol for preparing the PFGE gels for both species was the same; however, there
were only slight differences in the running conditions of the E. coli and K. pneumoniae
gels. The PFGE banding pattern for both species was analyzed using the BioNumerics
software, in which the DNA fragment sizes and genetic relationships were determined
using the Salmonella enterica ser. Braenderup as control and ladder to determine.
According to the PFGE gel analysis, similarity between the K. pneumoniae isolates
ranged from 61% to 100% (Figure 13). PFGE results for K. pneumoniae revealed that all
isolates clustered in two main clusters and a single outlier. Only two K. pneumoniae
isolates (06-012053 and 06-012055) were shown to be indistinguishable (i.e. 100%
similarity). However, in order to claim that these two particular isolates are identical
more thorough epidemiological work needs to be carried out. As for E. coli isolates, they
clustered in 4 main groups revealing an overall similarity of 64% (Figure 12). Similar to
K. pneumoniae, only 2 E. coli isolates (06-012012 and 06-012029), were shown to be
indistinguishable. For both species, there was no significant correlation found between
the AR patterns and genotypic (as judged by PFGE similarity). The lack of correlation is
due to the fact that the PFGE investigated the genotypic properties of the isolates, while
the

AR

patterns

tested

for
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the

ESBL

phenotype.

V.

DISCUSSION
Studies that characterize the AR mechanisms of ESBL-producing bacteria are

essential to monitor the evolution and spread of ESBL genes and to establish a sound AR
surveillance system that guides antibiotic prescription and use policies. ESBL-producing
organisms represent a major threat to public health, but may be effectively controlled,
partly by continuing epidemiological studies and solid pharmaceutical research aimed at
enhancing the development of new β-lactam antibiotics effective against ESBLproducing bacteria. The Middle East region currently lacks thorough epidemiological
studies investigating ESBL prevalence as well as robust surveillance systems. Therefore,
more ESBL characterization studies are needed in order to monitor the spread of ESBL
genes in the region and control the spread of ESBL-producing bacteria throughout
hospitals and in the community.
This study was conducted as part of a larger study that investigated the increasing
distribution of ESBL-producing bacteria among countries in the Persian Gulf and
particularly illustrated the increasing percentage of ESBL-producing bacteria in Oman.
Oman is a Middle Eastern country with a total population of 2.577 million, out of which
1.844 million are Omanis. Around 600,000 expatriates are known to live in Oman, most
of whom are from Pakistan, Egypt, The Philippines, Bangladesh and India - all
developing countries where the prevalence of ESBLs is known to be high (Encyclopedia
of the Nations, 2010).
In this study, 80% (40/50) of analyzed Gram-negative bacilli tested positive for
the ESBL phenotype. Compared to other published regional studies this percentage is
substantially high, suggesting the possible misuse of antibiotic therapy by the general
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public. A study at the intensive care unit (ICU) at the Royal Hospital in Oman showed
that every 100 patients treated in the ICU received an antibiotic treatment for 916 days
average, which were mainly third-generation cephalosporins, ciprofloxacin, amikacin,
and imipenem. According to this study the antibiotic consumption increased by 50%
from 1996 to 2000. With this substantial antibiotic use, it is not surprising to observe the
noticeable change in the microbial ecology in terms of high incidence of resistance
among the bacteria (Al-Lawati et al., 2000). Also as noted by Al-Tawfiq et al. (2010) that
a study from Oman reported that 31% of the urinary tract community E. coli were
resistant to ciprofloxacin. According to Al-Tawfiq et al. (2010) the high incidence of
antimicrobial resistance in the Middle East in general is due to number of reasons, such
as the wide availability of over-the-counter antibiotics, patient-self medication, lack of
public awareness in proper antibiotic use. Another explanation for the high percentage of
ESBL bacteria could be due to the regular movement of immigrants from developing
countries conducting manual labor in Oman.
The isolates provided for this study were collected in 2006 from the blood of
hospitalized patients suffering from nosocomial infections at public health hospitals in
Oman. Both ampicillin (a penicillin) and cephalothin (a cephalosporin) showed the
highest levels of resistance among the isolates, 94% and 92%, respectively. Both of these
antibiotic groups contain the characteristic beta-lactam ring that is targeted by the
different beta-lactamases produced by most Gram-negative and very few Gram-positive
bacteria. Alternatively, 100% of the tested strains were shown to be susceptible to
imipenem, which suggests the effectiveness of imipenem as a course of treatment for
patients suffering from nosocomial infections with ESBL positive bacterial species.
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Based on results from the E-test method, which allows the determination of the
MIC for each antibiotic tested, cephalothin was shown to have the highest level of
resistance (90% of strains); while, 50% of isolates were susceptible to cefepime. The
majority of isolates susceptible to cefepime were E. coli, with only one K. pneumoniae
isolate (06-012047) being susceptible. According to such findings it can be deduced that
cefepime would be more effective than cephalothin in the course of treatment against βlactamase-producing E. coli. In other words, the highest resistance levels found were
against a first-generation antibiotic, while the fourth-generation antibiotic was shown to
be more effective against E. coli isolates. This type of surveillance can help guide treating
physicians on which antibiotics are most appropriate and effective.
The main goal of performing PFGE on the isolates was to establish a genotypic map
and to determine whether or not PFGE genotype correlated with ESBL profile. The E.
coli dendogram contained 26 isolates that ranged in similarity from 64% to 100%. The 26
isolates clustered into 4 main clusters, out of which 14 isolates were shown to have 80%
or more similarity, resulting in 54% of the total number of E. coli isolates being ≥80%
similar. Isolates 06-012012 and 06-012029 were shown to be indistinguishable with
100% similarity. As for K. pneumoniae, the similarity among the 12 isolates ranged from
61% to 100 %, forming three main clusters. Among these three clusters, 7 isolates (58%)
were shown to be ≥80% similar. Also, isolates 06-012053 and 06-012055 were shown to
have 100% similarity making these two isolates indistinguishable, which according to
Tenover et al., indicates that these two isolates represent the same strain and suggest as
well that the isolates might have been part of an outbreak (Tenover et al., 1995). Since
54% of the E. coli isolates and 58% of the K. pneumoniae isolates were shown to be
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≥80% similar, the isolates for both bacterial species are considered to be closely related.
According to Tenover et al. isolates are assigned to the closely related category when the
PFGE pattern differs by 2 or 3 fragments from that of an outbreak. Such pattern changes
can be due to a single genetic event, such as a deletion, an insertion, or a point mutation
(Tenover et al., 1995). In this study in was determined that PFGE genotype (pattern) did
not correlate with antibiotic resistance profile (including the E-test). In other words, no
correlation could be established between the PFGE genotype and the ESBL phenotype.
This lack of correlation may be due to the fact that PFGE typing is based on differences
detected in the complete genome, while the ESBL typing only targets the specific ESBL
genetic markers.
Studies conducted in other regions have shown significant genotypic diversity among
isolates. According to Mendonca et al. (2009) a study in Portugal showed that 108 K.
pneumoniae isolates identified 65 different PFGE profile types out of which only two
turned out to have 100% similarity. In another study in Spain, Sorlozano et al. (2007)
showed that a different PFGE pattern was obtained for each of the 8 clinical isolates
studied. In Mexico, Mosqueda-Gomez et al. (2008) identified 54 different genotypes out
of the 121 isolates typed, in which 21 isolates were shown to be unique while the other
100 clustered in 33 different genotypes with each containing two to four isolates. Such
data from other studies show that the isolates in this study reveal a close genetic
relatedness as well as genotypic similarities unlike other regions. Similarly, the PFGE
results of a study in neonatal intensive care unit of a Kuwaiti hospital by Dashti et al.
(2010) showed that all isolates have an identical banding pattern, which indicates that the
bloodstream infections have been caused by a single clone of ESBL producing K.
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pneumoniae. PFGE is a very useful laboratory tool that helps identifying accurately an
outbreak situation. Since outbreak isolates are of the same species and known to be both
genetically and epidemiologically related, they generally share the same PFGE banding
pattern in terms of number of bands and band size.
Determining the AR mechanism of ESBL-producing strains is crucial because it helps
monitor the spread and transmission of these ESBL-producing genes as well as
maintaining a sound surveillance system that could provide guidance in appropriate
courses of treatment to those suffering such bacterial infections. According to these
analyses, all blaCTX-M positive isolates contained specifically the CTX-M-15 allelic
variant. This allele has been shown to be the most common CTX-M type allele in several
Middle Eastern countries, such as Kuwait, Lebanon, Egypt, and Saudi Arabia (Ensor et
al,, 2009; Moubareck et al,, 2005; Al-Agamy et al,, 2006; Khalaf et al,, 2009; Al-Agamy
et al,, 2009). Given the population mobility in and out of Oman from countries where
CTX-M is known to be prevalent, our high positive percentage (73%) could be related to
these regional movement events.
It has been observed that there is a high prevalence of CTX-M groups in both hospital
and community settings (Pitout et al., 2005), which obscures treatment for several
diseases such as urinary tract infections (Ehlers et al., 2009). According to Ehlers et al.
the occurrence of the CTX-M ESBLs affects public health by facilitating the spread of
infection from the hospital to the community. Therefore, such ESBL-producing bacteria,
especially the ones carrying CTX-M-type markers, require strict and efficient AR
surveillance systems and careful treatment policy guidance in order to prevent increasing
local AR rates (Ehlers et al., 2009).
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Based on sequence analyses for blaSHV, SHV-11, SHV-12, and SHV-1 were the only
allelic variants detected. Previous studies have shown that K. pneumoniae isolates are
most likely to have SHV genes as the predominant AR mechanism (Sturenburg and
Mack, 2003). A study in Iran by Shahcheraghi et al. (2007) demonstrated that SHV was
the dominant ESBL enzyme in K. pneumoniae strains. Another study also in Iran by
Feizabadi et al. (2010) revealed that the SHV types characterized were SHV-5, SHV-11,
and SHV-12: all found in K. pneumoniae strains. According to Lee et al. (2006), K.
pneumoniae produces class A chromosomal β-lactamases that are resistant to ampicillin,
ticarcillin, amoxicillin, and carbenicillin (Lee et al., 2006). In clinical K. pneumoniae
isolates, three families of chromosomal β-lactamases have been identified, SHV, LEN,
and OKP. Plasmid-mediated SHV-type ESBLs are very common in K. pneumoniae
isolates, in which SHV-12 is known to be common in south-east Asia (Lee et al., 2006).
In the study by Lee et al. the ESBL incidence was more common in K. pneumoniae
isolates containing the blaSHV-11 gene than it is in isolates containing the blaSHV-1 gene.
Also it was demonstrated that a number of the K. pneumoniae isolates carrying the
blaSHV-11 gene, also produced the ESBL SHV-12 subtype. However, the abundance of
SHV-12 in chromosomal blaSHV-11 gene-containing strains remains unknown (Lee et al.,
2006). Also it is worth mentioning that SHV-1 is not considered an ESBL type since it is
the parent enzyme from which precursors of ESBL SHV-type later evolved. According to
Lee et al. it is possible to identify a chromosomal SHV as well as a plasmid SHV in the
same isolate; therefore, the three SHV-types identified could have co-existed in a single
isolate if chromosomal DNA was extracted as well. Since blaSHV is known to be more
common in chromosomal DNA, this represents a limitation in the study because if
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additional to plasmid DNA, chromosomal DNA was extracted, the percentage of SHVpositive isolates might have been higher.
Several studies have shown the abundance of SHV-1, -11, and -12 types in
southwestern Asia and the Middle East. Bali et al. (2010) showed that SHV-12 in K.
pneumoniae and E. coli, is one of the most common ESBLs reported in Turkey. On the
other hand, in Palestine Hussein et al. (2009) demonstrated that among 60 Gram-negative
bacterial isolates from Palestinian hospitals in 2006, both blaSHV-1 and blaSHV-12 were
identified among ESBL types found.

As for blaTEM, analyses revealed that all isolates

were the TEM-1 subtype, which is not considered to be an ESBL as the TEM-1 subtype
is the parent enzyme from which more TEM precursors with ESBL phenotype later
originated. However, it is important to mention that such a result could be due to the use
of a particular set of primers that were unable to discriminate between the different TEM
families. In other words, the upstream and downstream primers are used to discriminate
between closely related TEM subtypes; however, in this case only the primer detecting
the core region of the gene was used and hence all isolates were characterized as TEM-1.
Our study suggest that TEM is not a significant factor conferring the ESBL phenotype on
E. coli and K. pneumoniae isolates from hospital-acquired infections in Oman. Due to the
fact that blaTEM-1 was shown to be the most common allele in this study, it can be
hypothesized that the bacteria might have a selective advantage expressing blaTEM-1 more
than other alleles in the blaTEM family. As was shown in studies in Turkey, Palestine, and
Kuwait, only blaTEM-1 was identified from the TEM family (Hussein et al., 2009; Bali et
al., 2010; Dashti et al., 2010). In Turkey 50% of the isolates were positive for TEM (Bali
et al., 2010), while a study in Saudi Arabia revealed that 84.1% of the isolates were TEM
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positive (Al-Agamy et al., 2009). The lack of ESBL TEM allele in several countries of
the Middle East region suggest decline of the ESBL TEM incidence compared to the
rapid increase of CTX-M prevalence. Regarding blaOXA, analysis showed that all the
isolates were OXA-1 which is known to be the most common OXA β-lactamase
especially in E. coli. Also OXA-1 is known to be the most common the Middle East
region, such as in Palestine, OXA-1 was identified in hospital isolates (Hussein et al.,
2009).
Since the AR mechanisms identified were all located in plasmids, this facilitates the
transfer and spread of these AR mechanisms in a geographical location. However, more
epidemiological and molecular characterization studies need to be carried out in order to
address this concept as well as monitor the spread of ESBL bacterial isolates in the
region.
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VI.

CONCLUSION
Antibiotic resistance among Gram-negative bacteria represents a global challenge

with the increased resistance to β-lactam antibiotics. According to Hanson (2010), there
are two main strategies by which scientists can overcome the problem of resistance; the
first is to develop new combinations of antibiotics faster than the development of
resistance. The second strategy is to develop the technology that would enable scientists
to carry out thorough and rapid surveillance of resistant bacteria both in community and
hospital settings. The rapid detection and identification of resistance can lead to judicious
antibiotic use, which will minimize the existence and development of more resistance.
This study revealed that a high incidence of ESBL-producing E. coli and K.
pneumoniae was present in hospital-acquired infections in Oman. Genotypic analysis
showed that both the E. coli and K. pneumoniae isolates were highly diverse suggesting
that it is more than a single strain circulating. DNA sequencing analysis revealed that
blaCTX-M-15 is the most prevalent ESBL producing gene found in hospital-acquired E. coli
and K. pneumoniae isolates in Oman. The other ESBL genes revealed by the analyses
were blaTEM-1, blaSHV-1, blaSHV-11, blaSHV-12, and blaOXA-1. This study highlighted the
importance of the need to improve the surveillance system of antibiotic resistance and
resistance mechanisms in the Middle East. In addition, it is crucial to organize public
awareness campaigns since they are necessary to encourage responsible antibiotic use.
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VIII.

TABLES AND FIGURES

Antibiotics Tested via the Disk Diffusion Method
Antibiotic
Discs
C
CRO
AN
SXT
TE
CIP
GM
AM
NA
IPM
FEP
ATM
SAM
CF
TIM
CPD
CAZ
CTX

Antibiotic Name
Chloramphenicol
Ceftriaxone
Amikacin
Trimethoprim-sulfamethoxazole
Tetracycline
Ciprofloxacin
Gentamicin
Ampicillin
Nalidixic Acid
Imipenem
Cefepime
Aztreonam
Ampicillin/Sulbactam
Cephalothin
Ticarcillin-clavulanic acid
Cefpodoxime
Ceftazidime
Cefotaxime

Antibiotic
Concentration
30 µg
30 µg
30 µg
1.25/23.75 µg
30 µg
5 µg
10 µg
10 µg
30 µg
10 µg
30 µg
30 µg
10/10 µg
30 µg
75/10 µg
10 µg
30 µg
30 µg

Table 1: table showing the 18 different antibiotics (AB Biodisk, Solna, Sweden) tested
via the disk diffusion method and the drug concentration for each particular antibiotic.
The ATCC® controls (E. coli 25922, S. aureus 25923, P. aeruginosa 27853) were used to
test the efficiency of the antibiotic discs.
Antibiotics Tested via E-test
E-Test Strips
TZ
PM
CE
TX

E-Test Name
Ceftazidime
Cefepime
Cephalothin
Ceftriaxone

Table 2: table showing the antibiotics (AB Biodisk, Solna, Sweden) tested via E-test. The
ATCC® control (E. coli 25922) was used to test the efficiency of the antibiotic strips.
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Forward and Reverse Primers Utilized for PCR of ESBL Genes
ESBL
Forward (5’—3’)

Reverse (5’ – 3’)

Size (bp)

blaTEM-1

CAG CGG TAA GAT CCT TGA GA

ACT CCC CGT CGT GTA GAT AA

643

blaSHV-1

GGC CGC GTA GGC ATG ATA GA

CCC GGC GAT TTG CTG ATT TC

714

blaCTX-M

AAC CGT CAC GCT GTT GTT AG

TTG AGG CTG GGT GAA GTA AG

766

blaOXA-1

AAT GGC ACC AGA TTC AAC TT

CTT GGC TTT TAT GCT TGA TG

595

Genes

Table 3: this table shows the primers used to amplify the four specific gene markers. The
TEM primer amplifies the blaTEM gene (858 bp), SHV primer amplifies the blaSHV gene
(861 bp), CTX-M primer amplifies the blaCTX-M gene (876 bp), and OXA primer
amplifies the blaOXA gene (869 bp) (Chen et al., 2004).
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Susceptibility %

Antimicrobial Susceptibility Spectrum in the 50
Clinical Isolates Tested
120%
100%
80%
60%
40%
20%
0%
IPM AN

C GM FEP SXT TIM SAM CAZ CIP NA CTX ATM CRO CPD TE AM CF
Antibiotic

Figure 1: A bar graph showing the susceptibility of the 50 isolates against the 18
different antibiotics tested, measured by the zone of inhibition using the CLSI standards.
All isolates (100%) were susceptible to IPM. AN was the second antibiotic to which 88%
of the isolates were susceptible. On the other hand, the majority of the isolates presented
the least susceptibility against AM and CF.

Antimicrobial Relative Resistance Spectrum in the
50 Clinical Isolates Tested
Intermediate %

50%
40%
30%
20%
10%
0%
TIM CAZ SAM FEP ATM TE CTX CRO C

AN CIP CF AM CPD NA GM SXT IPM

Antibiotic

Figure 2: A bar graph showing the percentage of the isolates that are found in the
intermediate region between the susceptibility and resistance, measured by the zone of
inhibition using the CLSI standards. According to the data 44% of the isolates were
resistant to TIM.
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Antimicrobial Resistance Spectrum in the 50
Clinical Isolates Tested
Resistance %

100%
80%
60%
40%
20%
0%
AM CF CPD NA TE CRO ATM CTX CIP SXT GM SAM CAZ FEP C TIM AN IPM
Antibiotic

Figure 3: A bar graph showing the resistance of the 50 isolates against the 18 different
antibiotics tested, measured by the zone of inhibition using the CLSI standards.
According to the data, 94% of the isolates were resistant to AM, while 92% were resistant
to CF making it the second in terms of resistance. On the other hand, all isolates (100%)
showed no resistance to IPM. Also, only 6% of the isolates were resistant to AN making
it the second antibiotic after IPM to have the highest efficacy.
Antimicrobial Resistance Spectrum Tested via E-Test
E-Test

Name

Resistance (%)

TZ
PM
CE
TX

Ceftazidime
Cefepime
Cephalothin
Ceftriaxone

24%
20%
90%
76%

Intermediacy
(%)
40%
30%
8%
4%

Susceptibility (%)
36%
50%
2%
20%

Table 4: The E-test data shows the four different antibiotics tested and the percentages of
the isolates resistant, intermediate, and susceptible to each particular antibiotic, by
determining the minimum inhibitory concentration using the CLSI standards. 76% of the
isolates were resistant to TX, while 50% of the isolates were susceptible to PM.
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Amplification of CTX-M:

Band size 766 bp

Figure 4: PCR gel showing the amplification of the blaCTX-M gene. Isolates were
categorized to be positive for blaCTX-M if a single sharp band has been amplified. 73% of
the 40 ESBL positive isolates possessed the blaCTX-M gene. A 100 bp DNA ladder was
used as a molecular marker (M).

Amplification of SHV:

Band size 720 bp

Figure 5: PCR gel showing the amplification of the blaSHV gene. Isolates were
categorized to be positive for blaSHV if a single sharp band has been amplified. 24% of the
40 ESBL positive isolates possessed the blaSHV gene. A 100 bp DNA ladder was used as a
molecular marker (M).

45

Amplification of TEM:

Band size 650 bp

Figure 6: PCR gel showing the amplification of the blaTEM gene. Isolates were
categorized to be positive for blaTEM if a single sharp band has been amplified. 68% of the
40 ESBL positive isolates possessed the blaTEM gene. A 100 bp DNA ladder was used as
a molecular marker (M).
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Amplification of OXA:

Band size 600 bp

Figure 7: PCR gel showing the amplification of the blaOXA gene. Isolates were
categorized to be positive for blaOXA if a single sharp band has been amplified. 60% of
the 40 ESBL positive isolates possessed the blaOXA gene. A 100 bp DNA ladder was used
as a molecular marker (M).
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CTX-M Nucleic Acid Sequence Alignment
CTXMF1_Oman(06-012014) -GCaACCGTCACGCTGTTGTTAGGAAGTGT GCCGCTGTAT GCGCAAACGG CGGACGTACA
CTXMF1_Oman(06-012015) GGCaACCGTC ACGCTGTTGT TAGGAAGTGT GCCGCTGTAT GCGCAAACGG
CGGACGTACA
CTXMF1_Oman(06-012016) GGCaACCGTC ACGCTGTTGT TAGGAAGTGT GCCGCTGTAT GCGCAAACGG
CGGACGTACA
CTXMF1_Oman(06-012014) GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG
CATTGATTAA
CTXMF1_Oman(06-012015) GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG
CATTGATTAA
CTXMF1_Oman(06-012016) GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG
CATTGATTAA
CTXMF1_Oman(06-012014) CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA
TGTGCAGCAC
CTXMF1_Oman(06-012015) CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA
TGTGCAGCAC
CTXMF1_Oman(06-012016) CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA
TGTGCAGCAC
CTXMF1_Oman(06-012014) CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC
CGAATCTGTT
CTXMF1_Oman(06-012015) CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC
CGAATCTGTT
CTXMF1_Oman(06-012016) CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC
CGAATCTGTT
CTXMF1_Oman(06-012014) AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA
TTGCGGAAAA
CTXMF1_Oman(06-012015) AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA
TTGCGGAAAA
CTXMF1_Oman(06-012016) AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA
TTGCGGAAAA
CTXMF1_Oman(06-012014) GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC
AGTACAGCGA
CTXMF1_Oman(06-012015) GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC
AGTACAGCGA
CTXMF1_Oman(06-012016) GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC
AGTACAGCGA
CTXMF1_Oman(06-012014) TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG
TCACCGCGTT
CTXMF1_Oman(06-012015) TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG
TCACCGCGTT
CTXMF1_Oman(06-012016) TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG
TCACCGCGTT
CTXMF1_Oman(06-012014) CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA
CGTTAAACAC
CTXMF1_Oman(06-012015) CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA
CGTTAAACAC
CTXMF1_Oman(06-012016) CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA
CGTTAAACAC
CTXMF1_Oman(06-012014) CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC
AAACTCTGCG
CTXMF1_Oman(06-012015) CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC
AAACTCTGCG
CTXMF1_Oman(06-012016) CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC
AAACTCTGCG
CTXMF1_Oman(06-012014) GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG
TGACATGGAT
CTXMF1_Oman(06-012015) GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG
TGACATGGAT
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CTXMF1_Oman(06-012016) GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG
TGACATGGAT
CTXMF1_Oman(06-012014) GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT
CCTGGGTTGT
CTXMF1_Oman(06-012015) GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT
CCTGGGTTGT
CTXMF1_Oman(06-012016) GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT
CCTGGGTTGT
CTXMF1_Oman(06-012014) GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG
TGATCTGGCC
CTXMF1_Oman(06-012015) GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG
TGATCTGGCc
CTXMF1_Oman(06-012016) GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG
TGATCTGGCC
CTXMF1_Oman(06-012014) AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC
CTAAGGCAGA
CTXMF1_Oman(06-012015) AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC
CTAAGGCAGA
CTXMF1_Oman(06-012016) AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC
CTAAGGCAGA
CTXMF1_Oman(06-012014) AAGCCGTCGC GATGTATtAG CGTC
CTXMF1_Oman(06-012015) AAGCCGTCGC GATGTATtAG CGTC
CTXMF1_Oman(06-012016) AAGCCGTCGC GATGTATtAG CgTC

Figure 8a: the DNA sequence alignment of 3 E. coli isolates for the CTX-M gene. This
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA
and amino acid sequence alignment.

CTX-M Amino Acid Sequence Alignment
CTXMF1_Oman(06-012014) ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST
CTXMF1_Oman(06-012015) ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST
CTXMF1_Oman(06-012016) ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST
CTXMF1_Oman(06-012014) SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE
LSAAALQYSD
CTXMF1_Oman(06-012015) SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE
LSAAALQYSD
CTXMF1_Oman(06-012016) SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE
LSAAALQYSD
CTXMF1_Oman(06-012014) NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR
CTXMF1_Oman(06-012015) NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR
CTXMF1_Oman(06-012016) NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR
CTXMF1_Oman(06-012014) NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG
TTNDIAVIWP
CTXMF1_Oman(06-012015) NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG
TTNDIAVIWP
CTXMF1_Oman(06-012016) NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG
TTNDIAVIWP
CTXMF1_Oman(06-012014) KDRAPLILVT YFTQPQPKAE SRRDVLA
CTXMF1_Oman(06-012015) KDRAPLILVT YFTQPQPKAE SRRDVLA
CTXMF1_Oman(06-012016) KDRAPLILVT YFTQPQPKAE SRRDVLA

Figure 8b: the amino sequence alignment of 3 E. coli isolates for the CTX-M gene. This
alignment after the DNA sequences have been translated to the amino acid sequences on
the BioEdit for further analysis using the Lahey Clinic webpage.
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TEM Nucleic Acid Sequence Alignment
06-012015 TATGTAATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC
06-012023 TGATGTCTGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC
06-012024 TGATGTCTGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC
06-012015 GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA
06-012023 GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA
06-012024 GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA
06-012015 TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT
06-012023 TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT
06-012024 TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT
06-012015 CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA
06-012023 CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA
06-012024 CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA
06-012015 ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA
06-012023 ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA
06-012024 ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA
06-012015 CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG
06-012023 CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG
06-012024 CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG
06-012015 ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA
06-012023 ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA
06-012024 ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA
06-012015 GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC
06-012023 GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC
06-012024 GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC
06-012015 ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC
06-012023 ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC
06-012024 ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC
06-012015 ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA
06-012023 ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA
06-012024 ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA
06-012015 ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG
06-012023 ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG
06-012024 ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG
06-012015 CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA
06-012023 CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA
06-012024 CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA
06-012015 ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA
06-012023 ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA
06-012024 ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA
06-012015 GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC
06-012023 GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC
06-012024 GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC
06-012015 TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA
06-012023 TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA
06-012024 TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA
06-012015 CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GCAGTTATCT ACACGACGGG GAGTCAGGCA
06-012023 CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT ACACGACGGG GAGTCAGGCA
06-012024 CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GCAGTTATCT ACACGACGGG GAGTCAGGCA
06-012015 ACTATG
06-012023 ACTATG
06-012024 ACTATG

50

Figure 9a: the DNA sequence alignment of 3 E. coli isolates for the TEM gene. This
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA
and amino acid sequence alignment.

TEM Amino Acid Sequence Alignment
06-012015 IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA
06-012023 IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA
06-012024 IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA
06-012015 LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST
06-012023 LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST
06-012024 LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST
06-012015 FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD
06-012023 FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD
06-012024 FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD
06-012015 NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR
06-012023 NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR
06-012024 NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR
06-012015 KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP
06-012023 KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP
06-012024 KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP
06-012015 DGKPSRIAVI YTTGSQATM
06-012023 DGKPSRIAVI YTTGSQATM
06-012024 DGKPSRIAVI YTTGSQATM

Figure 9b: the amino sequence alignment of 3 E. coli isolates for the TEM gene. This
alignment after the DNA sequences have been translated to the amino acid sequences on
the BioEdit for further analysis using the Lahey Clinic webpage.

51

OXA Nucleic Acid Sequence Alignment
06-012014 TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC
CAAAGGAATG
06-012015 TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC
CAAAGGAATG
06-012019 TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC
CAAAGGAATG
06-012014 GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT
TCGCAAGAAA
06-012015 GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT
TCGCAAGAAA
06-012019 GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT
TCGCAAGAAA
06-012014 TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA
ATCAAGACTT
06-012015 TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA
ATCAAGACTT
06-012019 TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA
ATCAAGACTT
06-012014 CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA
AATTTCACCA
06-012015 CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA
AATTTCACCA
06-012019 CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA
AATTTCACCA
06-012014 GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA
GCCATAGAAA
06-012015 GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA
GCCATAGAAA
06-012019 GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA
GCCATAGAAA
06-012014 ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA
CTGGTGCAGG
06-012015 ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA
CTGGTGCAGG
06-012019 ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA
CTGGTGCAGG
06-012014 ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC
AGGACATAAA
06-012015 ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC
AGGACATAAA
06-012019 ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC
AGGACATAAA
06-012014 TATGTTTTTG TGTCCGCACT TACAGGAA
06-012015 TATGTTTTTG TGTCCGCACT tACAGGAA
06-012019 TATGTTTTTG TGTCCGCACT TACAGGAA

Figure 10a: the DNA sequence alignment of 3 E. coli isolates for the OXA gene. This
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA
and amino acid sequence alignment.
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OXA Amino Acid Sequence Alignment
06-012014 YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF
06-012015 YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF
06-012019 YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF
06-012014 SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG
06-012015 SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG
06-012019 SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG
06-012014 FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG
06-012015 FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG
06-012019 FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG

Figure 10b: the amino sequence alignment of 3 E. coli isolates for the OXA gene. This
alignment after the DNA sequences have been translated to the amino acid sequences on
the BioEdit for further analysis using the Lahey Clinic webpage.
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SHV Nucleic Acid Sequence Alignment
06-012056 CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG
GATGCCGGTG
06-012055 CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG
GATGCCGGTG
06-012057 CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG
GATGCCGGTG
06-012056 ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG
TCAGCGAAAA
06-012055 ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG
TCAGCGAAAA
06-012057 ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG
TCAGCGAAAA
06-012056 ACATCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGCGCC GCCGCCATTA CCATGAGCGA
TAACAGCGCC
06-012055 ACACCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGTGCC GCCGCCATTA CCATGAGCGA
TAACAGCGCC
06-012057 ACACCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGCGCC GCCGCCATTA CCATGAGCGA
TAACAGCGCC
06-012056 GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG
ATCGGCGACA
06-012055 GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG
ATCGGCGACA
06-012057 GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG
ATCGGCGACA
06-012056 ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC
GCGACACCAC
06-012055 ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC
GCGACACCAC
06-012057 ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC
GCGACACCAC
06-012056 TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC
CCGTTCGCAA
06-012055 TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC
CCGTTCGCAA
06-012057 TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC
CCGTTCGCAA
06-012056 CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG
CTGCCGGCGG
06-012055 CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG
CTGTCGGCGG
06-012057 CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG
CTGCCGGCGG
06-012056 GCTGGTTTAT CGCCGATAAG ACCGGAGCTG GCGAACGGGG TGCGCGCGGG ATTGTCGCCC
TGCTTGGCCC
06-012055 GCTGGTTTAT CGCCGATAAG ACCGGAGCTG GAAAGCCAGC TGTgCGcGGC CGCGTAGGCC
TGATAGAAAT
06-012057 GCTGGTTTAT CGCCGATAAG ACCGGAGCTA GCAAGCGGGG TGCGCGCGGG ATTGTCGCCC
TGCTTGGCCC
06-012056 GAATAACAAA GCAGAGCGC
06-012055 GGATaaCTGG CCAGCGGCC
06-012057 GAATAACAAA GCAGAGCGC

Figure 11a: the DNA sequence alignment of 3 K. pneumoniae isolates for the SHV gene.
This alignment after the sequences have been imported from BioNumerics to BioEdit for
DNA and amino acid sequence alignment.
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SHV Amino Acid Sequence Alignment
06-012056 RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA
06-012055 RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA
06-012057 RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA
06-012056 ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ
06-012055 ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ
06-012057 ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ
06-012056 RQLLQWMVDD RVAGPLIRSV LPAGWFIADK TGAGERGARG IVALLGPNNK AER
06-012055 RQLLQWMVDD RVAGPLIRSV LSAGWFIADK TGAGKPAVRG RVGLIEMDNW PAA
06-012057 RQLLQWMVDD RVAGPLIRSV LPAGWFIADK TGASKRGARG IVALLGPNNK AER

Figure 11b: the amino sequence alignment of 3 K. pneumoniae isolates for the OXA
gene. This alignment after the DNA sequences have been translated to the amino acid
sequences on the BioEdit for further analysis using the Lahey Clinic webpage.
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AR Profile and DNA Sequencing Analysis

Isolate #

PCR Gel
Working
#

06-012011

-1

06-012012

1

06-012013

2

06-012014

3

06-012015

4

06-012016

5

06-012017

6

06-012018

7

Antibiotic
Resistance

E-Test
ESBL
Resistance
Pattern
E. coli Isolates

SXT, TE, CIP, GM,
CE
negative
AM, NA, CF
CRO, TE, CIP, AM, CE and TX positive
NA, CF, CPD, CTX
CRO, SXT, TE, CE and TX positive
CIP, GM, AM, NA,
FEP, ATM, SAM,
CF, CPD, CAZ,
CTX
CRO, AN, SXT, TE,
CE, TX,
positive
CIP, GM, AM, NA,
TZ, PM
FEP, ATM, SAM,
CF, CPD, CAZ,
CTX
CRO, SXT, TE,
CE, TX,
positive
CIP, GM, AM, NA,
TZ, PM
FEP, ATM, SAM
CF, CPD, CAZ,
CTX
CRO, TE, CIP, AM, CE, TX, TZ positive
NA, ATM, CF,
CPD, CAZ
C, SXT, TE, CIP,
CE, TX,
positive
GM, AM, NA, FEP,
TZ, PM
ATM, CF, CPD,
CAZ, CTX
SXT, TE, CIP, NA
None
Negative
56

BlaCTX-M

BlaTEM BlaOXA

BlaSHV

X

X

X

X

X

X

OXA-1

X

X

X

OXA-1

X

CTX-M-15

X

OXA-1

X

TEM-1 OXA-1

X

CTX-M-15

CTX-M-15

X

X

X

CTX-M-15

X

X

X

CTX-M-15

X

X

X

06-012019

8

06-012020

-2

06-012021

-3

06-012022

9

06-012023

10

06-012024

11

06-012025

12

06-012026

13

06-012027

14

06-012028

15

CRO, SXT, TE,
CIP, GM, AM, NA,
ATM, SAM, CF,
CPD, CTX
SXT, TE, CIP, AM,
NA, SAM, CF
SXT, TE, CIP, AM,
NA, SAM, CF
CRO, SXT, TE,
CIP, GM, AM, NA,
ATM, SAM, CF,
TIM, CPD, CTX
CRO, SXT, TE,
CIP, GM, AM, NA,
ATM, SAM, CF,
CPD, CTX
CRO, SXT, AM,
NA, ATM, CF,
CPD, CTX
CRO, SXT, TE,
CIP, GM, AM, NA,
FEP, ATM, SAM,
CF, CPD, CTX
CRO, TE, GM, AM,
NA, ATM, CF,TIM,
CPD, CTX
CRO, TE, GM, AM,
NA, ATM, SAM,
CF, TIM, CPD,
CTX
CRO, SXT, TE,

CE, TX,
PM

positive

CTX-M-15

X

OXA-1

X

TX

Negative

X

X

X

X

CE

Negative

X

X

X

X

CE and TX

positive

CTX-M-15

X

OXA-1

X

CE, TX,
PM

positive

CTX-M-15

TEM-1 OXA-1

X

CE and TX

positive

CTX-M-15

TEM-1 OXA-1

X

CE and TX

positive

CTX-M-15

CE and TX

positive

CE and TX

CE, TX,

57

X

OXA-1

X

CTX-M-15

TEM-1 OXA-1

X

positive

CTX-M-15

TEM-1 OXA-1

X

positive

CTX-M-15

X

OXA-1

X

06-012029

16

06-012030

17

06-012031

18

06-012032

19

06-012033
06-012034

-4
20

06-012035

21

06-012036

-5

06-012037

22

06-012038

-6

CIP, AM, NA, FEP,
ATM, SAM, CF,
CPD, CTX
CRO, TE, CIP, AM,
NA, CF, TIM, CPD,
CTX
CRO, SXT, TE,
CIP, GM, AM, NA,
CF, CPD, CAZ,
CTX
CRO, TE, CIP, AM,
NA, ATM, CF, TIM
TE, CIP, GM, AM,
NA, ATM, CF, CPD
NA & CF
C, CRO, SXT, TE,
CIP, GM, AM, NA,
FEP, ATM, SAM,
CF, CPD, CAZ,
CTX
C, CRO, SXT, CIP,
GM, AM, NA,
ATM, CF, TIM,
CPD, CTX
SXT, TE, CIP, AM,
NA
CRO, SXT, TE,
GM, AM, FEP,
ATM, SAM, CF,
CPD, CAZ, CTX
CIP

PM

CE and TX

positive

X

CE and TX

positive

X

CE and TX

positive

CTX-M-15

X

OXA-1

X

CE

positive

X

X

X

X

None
CE, TX,
TZ, PM

Negative
positive

X
CTX-M-15

X
X
TEM-1 OXA-1

X
X

CE and TX

positive

CTX-M-15

TEM-1 OXA-1

X

None

Negative

X

CE and TX

positive

CTX-M-15

None

Negative

X

58

X

X

TEM-1 OXA-1

X

X

TEM-1 OXA-1

X

X

X

X

X
X

X

06-012039

23

06-012040

24

06-012041

25

06-012042

26

06-012043
06-012044

-7
27

06-012045

28

06-012046

29

CRO, TE, GM, AM,
FEP, ATM, CF,
CPD, CAZ, CTX
CRO, CIP, AM,
NA, FEP, SAM, CF,
CPD, CAZ, CTX
C, CRO, SXT, TE,
AM, FEP, ATM,
SAM, CF, CPD,
CTX
CRO, AN, SXT, TE,
CIP, GM, AM, NA,
FEP, ATM, SAM,
CF, TIM, CPD,
CAZ, CTX
CIP & CF
CRO, SXT, TE,
CIP, AM, NA, CF,
CPD
C, CRO, SXT, TE,
AM, NA, ATM, CF,
CPD, CTX
CRO, SXT, TE,
AM, CF, TIM, CPD,
CTX

CE, TX,
TZ, PM

positive

X

TEM-1

X

X

CE and TX

positive

X

TEM-1

X

X

CE and TX

positive

CTX-M-15

TEM-1

X

X

CE, TX,
TZ, PM

positive

CTX-M-15

TEM-1 OXA-1

X

CE
CE and TX

Negative
Positive

X
X

X
TEM-1

X
X

X
X

CE and TX

Positive

CTX-M-15

TEM-1

X

X

CE and TX

Positive

CTX-M-15

TEM-1

X

X

Klebsiella Isolates
06-012047
K. oxytoca

30

CRO, AM, NA,
ATM, CF, CPD

CE, TX,
PM

positive

CTX-M-15

X

X

X

06-012048

-8

AM, NA, ATM, CF,
CPD

CE

Negative

X

X

X

X

59

06-012049
06-012050

-9
31

06-012051

32

06-012052

33

06-012053

34

06-012054

35

06-012055

36

06-012056

37

06-012057

38

06-012058

39

AM & CF
CE and TX Negative
C, CRO, SXT, TE, CE and TX positive
CIP, GM, AM, NA,
ATM, SAM, CF
CPD, CTX
CRO, TE, CIP, AM, CE, TX, TZ positive
NA, FEP, CF, CPD,
CAZ
SXT, TE, CIP, AM, CE and TX positive
SAM, CF, CPD,
CTX
CRO, GM, AM, CE and TX positive
FEP, ATM, SAM,
CF, CPD, CAZ,
CTX
AN, TE, CIP, GM, CE and TZ positive
AM, NA, ATM,
CPD, CAZ
CRO, GM, AM, CE and TX positive
FEP, ATM, SAM,
CF, CPD, CAZ,
CTX
CRO, SXT, CIP, CE, TX, TZ positive
AM, NA, FEP,
ATM, CF, CPD,
CAZ, CTX
C, CRO, SXT, TE, CE, TX, TZ positive
GM, AM, FEP,
ATM, SAM, CF,
CPD, CTX
CRO, AM, NA, CE and TZ positive
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X
CTX-M-15

X
X
TEM-1 OXA-1

X
SHV-1

CTX-M-15

TEM-1 OXA-1

SHV-11

CTX-M-15

TEM-1 OXA-1

SHV-11

X

TEM-1 OXA-1

SHV-1

X

TEM-1

X

X

CTX-M-15

TEM-1

X

SHV-12

CTX-M-15

X

X

SHV-11

CTX-M-15

X

X

SHV-12

X

X

X

SHV-12

06-012059

40

06-012060

41

ATM, CF, CPD,
CAZ, CTX
C, CRO, TE, CIP,
AM, NA, FEP,
ATM, CF, CPD,
CAZ, CTX
TE, CIP, AM, ATM,
CF, CPD, CAZ

CE and TX

positive

CTX-M-15

X

X

SHV-11

CE

positive

X

X

X

SHV-12

Table 5: table showing all the AR and sequencing data compiled. The gray shaded rows are the ESBL positive isolates, while the nonshaded rows represent the ESBL negative isolates. The second column from the left refers to the working number by which the
isolates are labeled in the previous PCR gels. The yellow highlighted row refers to isolate 06-012018 that is ESBL negative but was
positive for CTX-M-15.

61

E. coli PFGE Dendogram
Dice (Opt:1.50%) (Tol 1.5%-1.5%) (H>0.0% S>0.0%) [0.0%-98.3%]

100

PFGE-XbaI

90

80

70

PFGE-XbaI

06-012030
06-012046
06-012019
06-012039
06-012015
06-012045
06-012022
06-012031
06-012012
06-012029
06-012018
06-012014
06-012032
06-012016
06-012024
06-012040
06-012037
06-012023
06-012035
06-012028
06-012025
06-012013
06-012042
06-012041
06-012034
06-012044

Figure 12: the E. coli PFGE dendogram representing the genotypic relationship
among 26 E. coli isolates. The isolates clustered into four main clusters according to
their genotypic similarities. An overall similarity of 64% among the 4 clusters has
been established. Isolates 06-012012 and 06-012029 were shown to be
indistinguishable (100% similarity).
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K. pneumoniae PFGE Dendogram
Dice (Opt:1.50%) (Tol 1.5%-1.5%) (H>0.0% S>0.0%) [0.0%-98.3%]

PFGE-XbaI

100

80

PFGE-XbaI

06-012053
06-012055
06-012058
06-012052
06-012054
06-012056
06-012059
06-012057
06-012050
06-012047
06-012060
06-012051

Figure 13: the K. pneumoniae PFGE dendogram representing the genotypic
relationship among 12 K. pneumoniae isolates. The isolates clustered into two main
clusters according to their genotypic similarities and a single outlier. An overall
similarity between the isolates ranged from 61% to 100% has been established.
Isolates 06-012053 and 06-012055 were shown to be indistinguishable (100%
similarity).
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